Stemline Therapeutics Inc. (STML) Given Average Rating of “Buy” by Brokerages
Stemline Therapeutics Inc. (NASDAQ:STML) has received an average rating of “Buy” from the six ratings firms that are covering the firm. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.67.
A number of brokerages recently issued reports on STML. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a report on Wednesday, July 6th. Jefferies Group reissued a “buy” rating and issued a $23.00 price objective on shares of Stemline Therapeutics in a report on Friday, July 22nd. Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. Finally, Roth Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a report on Thursday, August 25th.
Stemline Therapeutics (NASDAQ:STML) traded up 0.38% during midday trading on Tuesday, hitting $13.18. 167,854 shares of the stock traded hands. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $13.75. The firm’s market cap is $234.93 million. The company’s 50-day moving average is $9.58 and its 200 day moving average is $7.32.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/stemline-therapeutics-inc-stml-given-average-rating-of-buy-by-brokerages.html
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. Stemline Therapeutics had a negative net margin of 4,419.18% and a negative return on equity of 44.59%. On average, analysts anticipate that Stemline Therapeutics will post ($2.11) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. raised its position in shares of Stemline Therapeutics by 11.8% in the second quarter. Franklin Resources Inc. now owns 2,102,200 shares of the biopharmaceutical company’s stock valued at $14,232,000 after buying an additional 222,170 shares during the period. Vanguard Group Inc. boosted its stake in shares of Stemline Therapeutics by 3.9% in the second quarter. Vanguard Group Inc. now owns 526,691 shares of the biopharmaceutical company’s stock valued at $3,566,000 after buying an additional 19,877 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Stemline Therapeutics by 7.8% in the second quarter. BlackRock Fund Advisors now owns 438,016 shares of the biopharmaceutical company’s stock valued at $2,965,000 after buying an additional 31,748 shares in the last quarter. State Street Corp boosted its stake in shares of Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock valued at $1,493,000 after buying an additional 4,197 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Stemline Therapeutics by 6.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 187,428 shares of the biopharmaceutical company’s stock valued at $1,269,000 after buying an additional 11,292 shares in the last quarter. 52.42% of the stock is owned by institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.